Guided by an expert WPI professor, you'll navigate the fast-paced journey of technology development, from inception to presentation ... a mini-project, and a poster. No prior programming experience is ...

Saol Therapeutics, Dr. Peter Stacpoole, and the other investigators plan to submit the results of the Phase III clinical program for publication. DCA is an investigational product that ...

DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes (T2D). Agonism of ...

today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85 th Scientific Sessions, being held from June 20-23 in Chicago, IL. “The amylin receptor is ...

The average snake caught has measured 12.6 feet in length, and the program has removed 277 breeding females. The Burmese python has a ... Ian Bartoszek gave a presentation May 15 at the Naples ...

Abstract Title: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study ASC30 is an investigational GLP-1R biased small molecule ...

today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85 th Scientific Sessions, being held from June 20-23 in Chicago, IL. “The amylin receptor is ...

Printing of the final posters is completed by Bates Post & Print. Students applying for admission to the college honors program will make an additional public presentation to the ES Committee faculty.

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in ...

Abstracts related to the EACR meeting will be published online following the presentation. For more information, please visit the EACR 2025 website. Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a ...

The two poster presentations at EHA today focused on clinical results based on the following goals of the study: Assessing safety and the ability of oral, once-daily mavorixafor to sustainably ...